BRIEF-Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants In Ngn-401 Gene Therapy Clinical Trial For Rett Syndrome

Reuters

12 Nov 2024

BRIEF-Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants In Ngn-401 Gene Therapy Clinical Trial For Rett Syndrome

Nov 11 (Reuters) - Neurogene Inc NGNE.O:

NEUROGENE REPORTS POSITIVE INTERIM EFFICACY DATA FROM FIRST FOUR LOW-DOSE PEDIATRIC PARTICIPANTS IN NGN-401 GENE THERAPY CLINICAL TRIAL FOR RETT SYNDROME
NEUROGENE INC - ALL PARTICIPANTS SHOW 2-POINT IMPROVEMENT IN CGI-I SCALE
NEUROGENE INC - PARTICIPANTS SHOW 28-52% IMPROVEMENT IN RETT SYNDROME BEHAVIOR QUESTIONNAIRE
NEUROGENE INC - LOW-DOSE NGN-401 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE
NEUROGENE INC - GAINS FDA ALIGNMENT ON POTENCY ASSAY STRATEGY FOR NGN-401
NEUROGENE INC - TO HALT NGN-101 CLN5 BATTEN DISEASE GENE THERAPY PROGRAM
NEUROGENE INC: PLANS TO PROVIDE AN UPDATE OF REGISTRATIONAL TRIAL DESIGN IN H1 2025

Source text: ID:nBw8xG8Vka

Further company coverage: NGNE.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2482769182"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2482769182\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2482769182?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-12 05:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482769182","market":"us","top_or_hot":-1,"title":"BRIEF-Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants In Ngn-401 Gene Therapy Clinical Trial For Rett Syndrome","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants In Ngn-401 Gene Therapy Clinical Trial For Rett Syndrome</title></head><body><p><span>Nov 11 (Reuters)</span><span> - </span>Neurogene Inc <span>NGNE.O</span>:</p><ul><li><p>NEUROGENE REPORTS POSITIVE INTERIM EFFICACY DATA FROM FIRST FOUR LOW-DOSE PEDIATRIC PARTICIPANTS IN NGN-401 GENE THERAPY CLINICAL TRIAL FOR RETT SYNDROME</p></li><li><p><a href=\"https://laohu8.com/S/NGNE\">NEUROGENE INC</a> - ALL PARTICIPANTS SHOW 2-POINT IMPROVEMENT IN CGI-I SCALE</p></li><li><p>NEUROGENE INC - PARTICIPANTS SHOW 28-52% IMPROVEMENT IN RETT SYNDROME BEHAVIOR QUESTIONNAIRE</p></li><li><p>NEUROGENE INC - LOW-DOSE NGN-401 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE</p></li><li><p>NEUROGENE INC - GAINS FDA ALIGNMENT ON POTENCY ASSAY STRATEGY FOR NGN-401</p></li><li><p>NEUROGENE INC - TO HALT NGN-101 CLN5 BATTEN DISEASE GENE THERAPY PROGRAM</p></li><li><p>NEUROGENE INC: PLANS TO PROVIDE AN UPDATE OF REGISTRATIONAL TRIAL DESIGN IN H1 2025</p></li></ul><p>Source text: <span>ID:nBw8xG8Vka</span></p><p>Further company coverage: <span>NGNE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants In Ngn-401 Gene Therapy Clinical Trial For Rett Syndrome</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants In Ngn-401 Gene Therapy Clinical Trial For Rett Syndrome\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-11-12 05:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants In Ngn-401 Gene Therapy Clinical Trial For Rett Syndrome</title></head><body><p><span>Nov 11 (Reuters)</span><span> - </span>Neurogene Inc <span>NGNE.O</span>:</p><ul><li><p>NEUROGENE REPORTS POSITIVE INTERIM EFFICACY DATA FROM FIRST FOUR LOW-DOSE PEDIATRIC PARTICIPANTS IN NGN-401 GENE THERAPY CLINICAL TRIAL FOR RETT SYNDROME</p></li><li><p><a href=\"https://laohu8.com/S/NGNE\">NEUROGENE INC</a> - ALL PARTICIPANTS SHOW 2-POINT IMPROVEMENT IN CGI-I SCALE</p></li><li><p>NEUROGENE INC - PARTICIPANTS SHOW 28-52% IMPROVEMENT IN RETT SYNDROME BEHAVIOR QUESTIONNAIRE</p></li><li><p>NEUROGENE INC - LOW-DOSE NGN-401 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE</p></li><li><p>NEUROGENE INC - GAINS FDA ALIGNMENT ON POTENCY ASSAY STRATEGY FOR NGN-401</p></li><li><p>NEUROGENE INC - TO HALT NGN-101 CLN5 BATTEN DISEASE GENE THERAPY PROGRAM</p></li><li><p>NEUROGENE INC: PLANS TO PROVIDE AN UPDATE OF REGISTRATIONAL TRIAL DESIGN IN H1 2025</p></li></ul><p>Source text: <span>ID:nBw8xG8Vka</span></p><p>Further company coverage: <span>NGNE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAZFJPX:1","article_id":"2482769182","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482769182","pubTimestamp":1731361587,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants In Ngn-401 Gene Therapy Clinical Trial For Rett SyndromeNov 11 (Reuters) - Neurogene Inc NGNE.O:N","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NGNE":"NEUROGENE INC"},"translate_title":"BRIEF-Neurogene报告了Ngn-401基因治疗Rett综合征临床试验中前四名低剂量儿科参与者的积极中期疗效数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NGNE":0.9},"content_text":"BRIEF-Neurogene Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants In Ngn-401 Gene Therapy Clinical Trial For Rett SyndromeNov 11 (Reuters) - Neurogene Inc NGNE.O:NEUROGENE REPORTS POSITIVE INTERIM EFFICACY DATA FROM FIRST FOUR LOW-DOSE PEDIATRIC PARTICIPANTS IN NGN-401 GENE THERAPY CLINICAL TRIAL FOR RETT SYNDROMENEUROGENE INC - ALL PARTICIPANTS SHOW 2-POINT IMPROVEMENT IN CGI-I SCALENEUROGENE INC - PARTICIPANTS SHOW 28-52% IMPROVEMENT IN RETT SYNDROME BEHAVIOR QUESTIONNAIRENEUROGENE INC - LOW-DOSE NGN-401 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILENEUROGENE INC - GAINS FDA ALIGNMENT ON POTENCY ASSAY STRATEGY FOR NGN-401NEUROGENE INC - TO HALT NGN-101 CLN5 BATTEN DISEASE GENE THERAPY PROGRAMNEUROGENE INC: PLANS TO PROVIDE AN UPDATE OF REGISTRATIONAL TRIAL DESIGN IN H1 2025Source text: ID:nBw8xG8VkaFurther company coverage: NGNE.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}